2020年12月2日,

12/02/2020 | 11:51am EST信息:*必填字段量子基因组获得高达1850万美元的前期和里程碑付款+两位数销售版税DongWha制药接受独家许可开发和商业化firibastat治疗难治疗/抗高血压在韩国巴黎12月02日2020(全球通讯社)——量子基因组学(泛欧交易所- FR0011648971 ALQGC增长),专门从事生物制药公司开发一种新的药物类,直接目标大脑治疗/抗高血压治疗困难,今天宣布它已经进入独家授权和协作协议DongWha制药开发和商业化firibastat大韩民国。后最后的合作伙伴在中国,这个新协议的第三步是量子基因组学”在亚洲的战略合作。根据协议条款,DongWha将获得独家商品化权firibastat治疗难治疗/抗高血压在韩国。此外,DongWha将加入全球的研究难以治疗/抗高血压在韩国。量子基因组学将收到前期和里程碑支付总额高达1850万美元,加上两位数销售版税。人口患有难以治疗和抗高血压在上述地区估计大约有一百万。”位于首尔,DongWha制药是完美的伴侣在韩国推出firibastat。120年来,DongWha制药建立了各种基础设施包括研发、分销和强劲的销售组织接近关键意见领袖。“自1970年以来,DongWha制药取得和维护长期合作关系与全球制药公司,其中狮子座和Menarini。“我们非常期待处理DongWha制药的临床研究,然后推出firibastat,”提到了让-菲利普•麦伦,量子基因组学的首席执行官。 “We are pleased to sign an exclusive contract for Firibastat of Quantum Genomics. Firibastat is a new class of drug entity that will satisfy the unmet needs of patients with difficult-to-treat/resistant hypertension or heart failure, and we believe that this partnership will increase our market share in the cardiovascular field. In addition, we will continue to expand our pipelines through the open innovation,” mentioned Ki-Whan Park, President and CEO of DongWha Pharm. About DongWha Pharm Established as the first Korean pharmaceutical company in 1897, DongWha is the most representative pharmaceutical company with high brand power. DongWha is a full-fledge equipped pharmaceutical company with its R&D center, manufacturing facility and nationwide sales and marketing network. DongWha has developed reliable long-term partnerships with global companies such as Leo, Menarini, Pfizer and so on. Under the spirit of the establishment “Serving customers through making good medicines and operating with the resulting revenues”, DongWha has dedicated to developing innovative drugs. About Quantum Genomics Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years). Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF). For more information, please visit www.quantum-genomics.com , or follow us on Twitter and LinkedIn Contact information